SCHEMBL1341982

SCHEMBL1341982

Cn1nnnc1Sc1sc(NC(=O)Nc2ccc(F)cc2C(=O)C2CCCC2)nc1CC(=O)O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.34
TP53 P04637 2/20 0.34
NPC1 O15118 8/20 0.33
RAB9A P51151 7/20 0.33
TSHR P16473 1/20 0.33
GCK P35557 2/20 0.33
MAPT P10636 3/20 0.32
KDM4E B2RXH2 1/20 0.32
CASP3 P42574 1/20 0.32
SENP7 Q9BQF6 1/20 0.32
POLB P06746 1/20 0.32
ALDH1A1 P00352 2/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
GAA P10253 1/20 0.32
MAPK14 Q16539 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1342757 0.92 LMNA (0.40) LMNANPC1RAB9ATSHRMAPT
SCHEMBL1340449 0.91 MAPT (0.36) LMNANPC1RAB9ATSHRGCK
SCHEMBL1341830 0.91 LMNA (0.36) LMNANPC1RAB9ATSHRMAPT
SCHEMBL1342032 0.90 ALDH1A1 (0.39) LMNATP53NPC1RAB9ATSHR
SCHEMBL1341891 0.90 MAPT (0.42) LMNANPC1RAB9AMAPTKDM4E
SCHEMBL1342042 0.90 RAB9A (0.33) LMNATP53NPC1RAB9ATSHR
SCHEMBL1342293 0.89 NPC1 (0.36) LMNATP53NPC1RAB9ATSHR
SCHEMBL1342578 0.89 ALDH1A1 (0.33) LMNATP53NPC1RAB9ATSHR
SCHEMBL1342566 0.89 LMNA (0.35) LMNATP53NPC1RAB9ATSHR
SCHEMBL1342065 0.87 RAB9A (0.34) LMNANPC1RAB9ATSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063081-B2 N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-11-22 US disclosed
US-7897628-B2 {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-03-01 US disclosed
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents VTV THERAPEUTICS LLC 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents GCK, GCKR, PDK2 LMNA 4011/4885TP53 2961/4885NPC1 2201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.